大量的临床和实验证据表明，巨噬细胞在癌症免疫治疗中发挥着关键作用。巨噬细胞通过受体信号调节蛋白α（SIRPα）接收受体，调节着集团分化抗原47（CD47）信号，该受体存在于健康和恶性细胞上，从而发出“别吃我”的信号，控制着巨噬细胞介导的吞噬作用。越来越多的证据表明，阻断CD47与SIRPα的相互作用可以增强巨噬细胞对癌细胞的清除作用。此外，抑制CD47/SIRPα的相互作用能够增加抗原交叉呈递，导致T细胞的启动和被激活的适应性抗肿瘤免疫反应。因此，抑制CD47/SIRPα轴对肿瘤免疫治疗具有重要影响。关于CD47单克隆抗体的研究处于研究前沿，获得了令人印象深刻的结果。然而，血液毒性，特别是贫血，已成为CD47单克隆抗体最常见的不良反应。更具有特异性的靶向药物（即双特异性抗体、SIRPα/Fc融合蛋白抗体和小分子抑制剂）已经开发出来，以减少血液毒性。在这里，我们从结构、功能和临床试验的角度，包括药物开发中的全面概述，回顾了CD47拮抗剂在淋巴瘤和血液肿瘤治疗中的现有用途。© 2023. 作者（们）保留所有权利。

Extensive clinical and experimental evidence suggests that macrophages play a crucial role in cancer immunotherapy. Cluster of differentiation (CD) 47, which is found on both healthy and malignant cells, regulates macrophage-mediated phagocytosis by sending a "don't eat me" signal to the signal regulatory protein alpha (SIRPα) receptor. Increasing evidence demonstrates that blocking CD47 interaction with SIRPα can enhance cancer cell clearance by macrophages. Additionally, inhibition of CD47/SIRPα interaction can increase antigen cross-presentation, leading to T-cell priming and an activated adaptive antitumor immune response. Therefore, inhibiting CD47/SIRPα axis has a significant impact on tumor immunotherapy. Studies on CD47 monoclonal antibodies are at the forefront of research, and impressive results have been obtained. Nevertheless, hematotoxicity, especially anemia, has become the most common adverse effect of the CD47 monoclonal antibody. More specific targeted drugs (i.e., bispecific antibodies, SIRPα/Fc fusion protein antibodies, and small-molecule inhibitors) have been developed to reduce hematotoxicity. Here, we review the present usage of CD47 antagonists for the treatment of lymphomas and hematologic neoplasms from the perspectives of structure, function, and clinical trials, including a comprehensive overview of the drugs in development.© 2023. The Author(s).